Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market (opens original article in a new tab)

Next-generation DNA repair inhibitors, particularly PNKP inhibitors, are gaining attention for their potential to capture a significant share of the expanding oncology market, with Onco-Innovations Limited leading in this field due to its exclusive technologies and promising preclinical results.

• Next-generation DNA repair inhibitors, like PNKP inhibitors, are emerging as a significant drug class with potential to capture a large share of the expanding DNA Damage Response market.
• Onco-Innovations Limited holds exclusive worldwide rights to PNKP inhibitor technologies, including nanoparticle delivery systems and synthetic lethality applications, positioning it as a leader in this space.
• Preclinical studies show ONC010, a PNKP inhibitor, significantly extended survival in mice with colorectal cancer and demonstrated a favorable toxicity profile.